Common Long-Term Risks Reported with Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries infection risks that persist or worsen over years of use. Upper respiratory infections affect 14-18% of patients in trials lasting up to 5 years, with rates rising in extended data.[1] Serious infections like cellulitis or pneumonia occur in about 1-2% annually, potentially leading to hospitalization.[2]
Increased Cancer Risk Over Time
Long-term studies (up to 5 years) show a slight elevation in malignancies, including non-melanoma skin cancers (1.2% incidence vs. 0.7% in placebo). Solid tumors and lymphomas appear at low rates (0.5-1 per 100 patient-years), though causality remains unproven due to underlying disease factors in autoimmune patients.[1][3]
Inflammatory Bowel Disease Flare-Ups
New-onset or worsening Crohn's disease or ulcerative colitis emerges in 1-2% of users, often within the first year but persisting long-term. Rates are higher (up to 3%) in those with prior gut issues; monitoring via symptoms or endoscopy is advised.[2][4]
Impact on Vaccinations and Immunity
Live vaccines are contraindicated due to immunosuppression, risking severe reactions. Long-term users show reduced responses to non-live vaccines like flu shots, increasing infection vulnerability during outbreaks.[1]
Rare but Serious Long-Term Concerns
- Hypersensitivity: Anaphylaxis or serum sickness-like reactions in <1%, potentially recurring with re-exposure.
- Neutropenia: Low white blood cell counts in 2-3%, reversible but raising infection odds if prolonged.
- Bone and Joint Effects: No major osteoporosis signal, but theoretical IL-17 role in bone health prompts monitoring in elderly users.[3]
Real-world data from registries (e.g., 10-year psoriasis cohorts) confirm these risks stabilize rather than escalate after year 2, but cumulative exposure heightens monitoring needs.[4] Discontinuation often reverses risks within months.
[1]: https://www.cosentyx.com/important-safety-information
[2]: Novartis Cosentyx Prescribing Information (2023)
[3]: FDA Adverse Event Reporting System (FAERS) analysis
[4]: PubMed - Long-term safety of secukinumab (e.g., CLEAR/SCULPTURE extensions)